NO830697L - Homogent menneske-immun-interferon og fremstilling derav - Google Patents
Homogent menneske-immun-interferon og fremstilling deravInfo
- Publication number
- NO830697L NO830697L NO830697A NO830697A NO830697L NO 830697 L NO830697 L NO 830697L NO 830697 A NO830697 A NO 830697A NO 830697 A NO830697 A NO 830697A NO 830697 L NO830697 L NO 830697L
- Authority
- NO
- Norway
- Prior art keywords
- interferon
- column
- human
- immune
- active fractions
- Prior art date
Links
- 102000014150 Interferons Human genes 0.000 title claims description 32
- 108010050904 Interferons Proteins 0.000 title claims description 32
- 229940079322 interferon Drugs 0.000 title claims description 27
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 30
- 230000001965 increasing effect Effects 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 108010062580 Concanavalin A Proteins 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000000741 silica gel Substances 0.000 claims description 9
- 229910002027 silica gel Inorganic materials 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 238000004811 liquid chromatography Methods 0.000 claims description 6
- 238000012784 weak cation exchange Methods 0.000 claims description 6
- -1 carboxymethyl silica gel Chemical compound 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000008057 potassium phosphate buffer Substances 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 4
- 229920002684 Sepharose Polymers 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 230000003028 elevating effect Effects 0.000 claims 4
- 239000008366 buffered solution Substances 0.000 claims 2
- 244000228957 Ferula foetida Species 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000000084 colloidal system Substances 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 description 15
- 102000008070 Interferon-gamma Human genes 0.000 description 15
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108010047620 Phytohemagglutinins Proteins 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000001885 phytohemagglutinin Effects 0.000 description 10
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 10
- 238000000746 purification Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Substances OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000001103 potassium chloride Substances 0.000 description 7
- 235000011164 potassium chloride Nutrition 0.000 description 7
- 239000000872 buffer Substances 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 229940047124 interferons Drugs 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 229910000160 potassium phosphate Inorganic materials 0.000 description 5
- 235000011009 potassium phosphates Nutrition 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 102000006992 Interferon-alpha Human genes 0.000 description 4
- 108010047761 Interferon-alpha Proteins 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000003226 mitogen Substances 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 229910000318 alkali metal phosphate Inorganic materials 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 3
- 239000002644 phorbol ester Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108010033737 Pokeweed Mitogens Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 229910001508 alkali metal halide Inorganic materials 0.000 description 2
- 150000008045 alkali metal halides Chemical class 0.000 description 2
- 229910052936 alkali metal sulfate Inorganic materials 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 231100000655 enterotoxin Toxicity 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000272168 Laridae Species 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 101150107341 RERE gene Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002842 cytophatogenic effect reduction assay Methods 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- HOVAGTYPODGVJG-VEIUFWFVSA-N methyl alpha-D-mannoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-VEIUFWFVSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000004633 phorbol derivatives Chemical class 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000005373 porous glass Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35344282A | 1982-03-01 | 1982-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO830697L true NO830697L (no) | 1983-09-02 |
Family
ID=23389118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO830697A NO830697L (no) | 1982-03-01 | 1983-02-28 | Homogent menneske-immun-interferon og fremstilling derav |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0087686A3 (xx) |
| JP (1) | JPS58159417A (xx) |
| KR (1) | KR840003422A (xx) |
| AU (1) | AU1181283A (xx) |
| DK (1) | DK104283A (xx) |
| ES (1) | ES8407499A1 (xx) |
| FI (1) | FI830557L (xx) |
| GB (1) | GB2119383A (xx) |
| GR (1) | GR77910B (xx) |
| GT (1) | GT198301619A (xx) |
| IL (1) | IL67978A0 (xx) |
| MC (1) | MC1499A1 (xx) |
| MT (1) | MTP924B (xx) |
| MW (1) | MW783A1 (xx) |
| NO (1) | NO830697L (xx) |
| NZ (1) | NZ203364A (xx) |
| PT (1) | PT76310B (xx) |
| ZA (1) | ZA83768B (xx) |
| ZW (1) | ZW4683A1 (xx) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0107498B1 (en) * | 1982-10-25 | 1990-05-16 | Genentech, Inc. | Synergistic human interferon activity |
| IL67896A (en) * | 1983-02-13 | 1987-03-31 | Yeda Res & Dev | Two biologically active human gama interferon subtypes,purification thereof and pharmaceutical compositions containing them |
| DE3484374D1 (de) * | 1983-08-04 | 1991-05-08 | Green Cross Corp | Gamma-interferonzusammensetzung. |
| US4681930A (en) * | 1983-09-20 | 1987-07-21 | Hoffmann-La Roche Inc. | Immune interferon and a method for its extraction and purification |
| US4855238A (en) | 1983-12-16 | 1989-08-08 | Genentech, Inc. | Recombinant gamma interferons having enhanced stability and methods therefor |
| MX9203641A (es) * | 1983-12-16 | 1992-07-01 | Genentech Inc | Interferones gamma recombinantes que poseen estabilidad mejorada y metodos biotecnologicos para su obtencion. |
| US4946674A (en) * | 1984-10-05 | 1990-08-07 | Bioferon Biochemische Substanzen Gmbh & Co. | Process for treatment of rheumatic diseases |
| IL76591A0 (en) * | 1984-10-05 | 1986-02-28 | Bioferon Biochem Substanz | Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof |
| GR860758B (en) * | 1985-03-25 | 1986-07-21 | Schering Corp | Stable gamma - interferon formulation |
| GB8508340D0 (en) * | 1985-03-29 | 1985-05-09 | Creighton T E | Production of protein |
| GB8522336D0 (en) * | 1985-09-09 | 1985-10-16 | Biogen Nv | Composition for treatment of allergies |
| WO1987005518A1 (en) * | 1986-03-17 | 1987-09-24 | Schering Corporation | Treatment of cancers with gamma interferon |
| IL84170A0 (en) * | 1986-10-17 | 1988-03-31 | Interferon Sciences Inc | Method for detecting interferon |
| DE3869789D1 (de) * | 1987-01-20 | 1992-05-14 | Schering Corp | Behandlung von einigen leukaemien mit einer zusammensetzung von interferon-gamma und interferon-alpha. |
| DE102007050165B4 (de) * | 2007-10-19 | 2010-06-17 | Stiftung Tierärztliche Hochschule Hannover | Stabilisierte Lösung, Verfahren zu deren Herstellung sowie deren Verwendung und Arzneimittel in Form einer stabilisierten Lösung |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA120527A (en) * | 1907-05-18 | 1909-09-14 | James Mccallum Robertson | Prepay device for meters |
| CA120526A (en) * | 1909-05-05 | 1909-09-14 | Robert A. Reynolds | Internal combustion engine |
| CA130300A (en) * | 1910-08-03 | 1911-01-03 | John W. Ziegler | Current wheel |
| CA154712A (en) * | 1914-01-02 | 1914-03-31 | William Francis Fox | Photographic process |
| CA179241A (en) * | 1917-03-02 | 1917-09-11 | John Totterdale | Container |
| US4241174A (en) * | 1978-11-24 | 1980-12-23 | Hoffmann-La Roche Inc. | Interferon assay |
| IN150740B (xx) * | 1978-11-24 | 1982-12-04 | Hoffmann La Roche | |
| CH648331A5 (de) * | 1979-07-31 | 1985-03-15 | Hoffmann La Roche | Homogenes fibroblasten-interferon und dessen herstellung. |
-
1983
- 1983-02-04 ZA ZA83768A patent/ZA83768B/xx unknown
- 1983-02-17 EP EP83101522A patent/EP0087686A3/en not_active Withdrawn
- 1983-02-18 MT MT924A patent/MTP924B/xx unknown
- 1983-02-18 FI FI830557A patent/FI830557L/fi not_active Application Discontinuation
- 1983-02-21 ZW ZW46/83A patent/ZW4683A1/xx unknown
- 1983-02-21 MW MW7/83A patent/MW783A1/xx unknown
- 1983-02-22 NZ NZ203364A patent/NZ203364A/en unknown
- 1983-02-23 IL IL67978A patent/IL67978A0/xx unknown
- 1983-02-24 AU AU11812/83A patent/AU1181283A/en not_active Abandoned
- 1983-02-25 MC MC831624A patent/MC1499A1/xx unknown
- 1983-02-28 GT GT198301619A patent/GT198301619A/es unknown
- 1983-02-28 PT PT76310A patent/PT76310B/pt unknown
- 1983-02-28 JP JP58031081A patent/JPS58159417A/ja active Pending
- 1983-02-28 GR GR70628A patent/GR77910B/el unknown
- 1983-02-28 ES ES520164A patent/ES8407499A1/es not_active Expired
- 1983-02-28 GB GB08305506A patent/GB2119383A/en not_active Withdrawn
- 1983-02-28 KR KR1019830000822A patent/KR840003422A/ko not_active Application Discontinuation
- 1983-02-28 NO NO830697A patent/NO830697L/no unknown
- 1983-02-28 DK DK104283A patent/DK104283A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR840003422A (ko) | 1984-09-08 |
| ES520164A0 (es) | 1984-10-01 |
| AU1181283A (en) | 1983-09-08 |
| MC1499A1 (fr) | 1983-11-17 |
| MW783A1 (en) | 1984-09-12 |
| GB2119383A (en) | 1983-11-16 |
| PT76310B (en) | 1986-02-12 |
| GT198301619A (es) | 1984-08-21 |
| DK104283D0 (da) | 1983-02-28 |
| FI830557L (fi) | 1983-09-02 |
| EP0087686A3 (en) | 1985-09-18 |
| GR77910B (xx) | 1984-09-25 |
| ZW4683A1 (en) | 1983-10-19 |
| ES8407499A1 (es) | 1984-10-01 |
| MTP924B (en) | 1984-05-03 |
| NZ203364A (en) | 1986-07-11 |
| EP0087686A2 (en) | 1983-09-07 |
| GB8305506D0 (en) | 1983-03-30 |
| PT76310A (en) | 1983-03-01 |
| IL67978A0 (en) | 1983-06-15 |
| FI830557A0 (fi) | 1983-02-18 |
| JPS58159417A (ja) | 1983-09-21 |
| DK104283A (da) | 1983-09-02 |
| ZA83768B (en) | 1983-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yip et al. | Partial purification and characterization of human gamma (immune) interferon. | |
| US6471500B1 (en) | Process for producing erythropoietin containing no animal proteins | |
| Staehelin et al. | Purification and characterization of recombinant human leukocyte interferon (IFLrA) with monoclonal antibodies. | |
| NO830697L (no) | Homogent menneske-immun-interferon og fremstilling derav | |
| Lai et al. | Chemistry of cholera toxin: the subunit structure | |
| Peumans et al. | Isolation and partial characterization of wheat-germ-agglutinin-like lectins from rye (Secale cereale) and barley (Hordeum vulgare) embryos | |
| EP0110302A2 (en) | Method for producing monomeric interferons | |
| Tsuda | Purification and characterization of a lectin from rice bran | |
| US5196323A (en) | Process for preparing and purifying alpha-interferon | |
| US5593667A (en) | Recombinant immune interferon having an intact carboxyl terminus | |
| CA1231306A (en) | Purification of interferon | |
| Carra | Purification and N-terminal analyses of algal biliproteins | |
| NO159610B (no) | Fremgangsm te ved rensing av et immuninterferonfrag | |
| US4765903A (en) | Purification of monomeric interferon | |
| US4534906A (en) | Removal of impurities from human leukocyte interferon preparations | |
| GB2055384A (en) | Homogeneous fibroblast interferon and method for manufacture thereof | |
| US4908432A (en) | Novel polypeptide having gamma-interferon activity | |
| US4617378A (en) | Purification of biologically active human immune interferon | |
| CA1340281C (en) | Process for preparing and purifying alpha-interferon | |
| JPS6261040B2 (xx) | ||
| Garattini et al. | Human liver alkaline phosphatase, purification and partial sequencing: homology with the placental isozyme | |
| EP0199568A2 (en) | Method for purifying interferon and composition of matter produced thereby | |
| Kenny et al. | [64] Purification of human fibroblast interferon produced in the absence of serum by cibacron blue F3GA-agarose and high-performance liquid chromatography | |
| EP0396555B1 (en) | Purification of monomeric interferon | |
| MIYATA et al. | Pruification of Natural Human Interferon-Gamma by Antibody Affinity Chromatography: Analysis of Constituent Protein Species in the Dimers |